Goldman Sachs Maintains Sell on Elanco Animal Health, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich maintains a Sell rating on Elanco Animal Health (ELAN) but raises the price target from $12.5 to $14.

February 27, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs maintains a Sell rating on Elanco Animal Health but increases the price target from $12.5 to $14.
The maintenance of a Sell rating by a major analyst firm like Goldman Sachs generally indicates a bearish outlook on the stock, suggesting that the analyst believes the stock's market price will decline in the short term. However, the increase in the price target from $12.5 to $14 suggests a slightly less negative outlook than previously held. This could mean that while the overall sentiment is still bearish, there may be some factors that could limit the downside or even provide a slightly better performance than initially expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100